TMC125 demonstrates strong antiviral effect in HIV

October 29, 2001

First clinical results in short-term study are promising

ATHENS, Greece; Monday 29th, October 2001 - Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATH) demonstrate an average reduction in the amount of HIV in patients' plasma (viral load) of 99% after one week of treatment using Tibotec-Virco's novel, new candidate drug TMC125, a potent non-nucleoside reverse transcriptase inhibitor.

Study C208 was a phase IIa double-blind, placebo-controlled trial examining the safety and efficacy of TMC125 monotherapy in 18 previously untreated HIV-positive individuals over one week. The trial was conducted in Moscow and St. Petersburg in Russia and all participants were offered open label state-of-the-art combination therapy after the one-week study.

"These are promising results for people living with HIV" said Joep Lange, MD, Head of the Antiviral Therapy Evaluation Center (IATEC) at the Academic Medical Center in Amsterdam. "These early results indicate that TMC125 has a rapid and strong antiviral effect in the short term. The challenge will now be to study the drug over a longer period of time to see if this early promise is fulfilled."

Researchers noted that while the average decrease in HIV viral load was 99%, some study participants experienced decreases of over 99.9%. The reductions in viral load ranged from 1.1 log up to 3.4 log. Eight of the 12 subjects who received TMC125 had their viral loads reduced to less than 400 copies of HIV/ml, with two subjects below the 50-copy limit of a more sensitive test. None of the subjects experienced any rebound in viral load during the short study period and there was no evidence of the development of drug resistance. TMC125 was very well tolerated during this study with no apparent differences in side effects between TMC125 and placebo.

"We are obviously delighted that TMC125 has performed so well in this study," commented Neil Graham MD, Vice President of the Medical Department, Tibotec-Virco. "These early clinical data suggest that TMC125 could become a major contributor to more effective HIV therapy in the future." Additional clinical trials are ongoing to study the use of TMC 125 in NNRTI-experienced patients. Previous laboratory research has demonstrated that TMC 125 and other NNRTIs under development at Tibotec-Virco are highly active against strains of HIV that are resistant to the current NNRTIs.


Tibotec-Virco is a multinational biotechnology company with headquarters in Belgium and operating subsidiaries in the United States and Ireland.

Tibotec-Virco develops new drugs and individualised disease management products and services for HIV and other infectious diseases with the ultimate aim of enhancing and extending peoples' lives. The Company applies the latest techniques in drug discovery, pharmacogenomics, molecular biology, and artificial intelligence to its research and development programmes.

The company was formed from the merger of Virco Group NV and Tibotec Group NV on March 14, 2001 and brings together the complementary expertise of Tibotec in drug discovery and development and that of Virco in pharmacogenomics and molecular diagnostics.

The Company is focusing on the discovery and development of HIV/AIDS compounds that are active against strains of HIV that have developed drug resistance (a major cause of treatment failure). TMC125, a novel NNRTI, and TMC114, a protease inhibitor, are in clinical development.

Tibotec-Virco is widely regarded as a world leader in HIV resistance testing. The Company has built the world's largest relational database of more than 100,000 HIV genotypes and phenotypes; the VirtualPhenotype™ test, which combines the best features of both genotyping and phenotyping by using information from this immense database, has been developed to give physicians the most comprehensive, accurate and reliable resistance information available.
For further information, please visit Tibotec-Virco's website:

Cooney Waters Group, Inc.

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to